Company profile
Beyond Air, Inc.
NASDAQ:XAIRMedical/Dental Instruments
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Nitric Oxide | phase3 | — | 5 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05351502 | phase1 | unknown | 2022-08-14 | 2025-05-30 | Beyond Air Inc. | A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors |
| NCT04060979 | phase2 | completed | 2019-11-06 | 2020-03-02 | Beyond Air Inc. | Evaluation of Two Doses of Nitric Oxide (NO) Given Intermittently Via Inhalation to Subjects With Bronchiolitis |
| NCT03053388 | phase3 | completed | 2017-03-05 | 2018-04-28 | Beyond Air Inc. | Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Bronchiolitis |
| NCT01958944 | phase1_2 | completed | 2013-12-01 | 2015-11-01 | Beyond Air Inc. | Evaluation of the Safety and Tolerability of Inhaled Nitric Oxide to Subjects With Cystic Fibrosis |
| NCT01768884 | phase1_2 | completed | 2013-01-01 | 2016-01-01 | Beyond Air Inc. | Evaluation of the Safety and Tolerability of Nitric Oxide (NO) Via Inhalation to Subjects With Bronchiolitis |
FDA applications (0)
No records yet.